Search Results for "R"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for R. Results 221 to 230 of 996 total matches.

Drugs for Acute Spinal Cord Injury

   
The Medical Letter on Drugs and Therapeutics • Aug 06, 1993  (Issue 902)
syndrome has been reported in patients treated with gangliosides (A Figueras et al, BMJ, 305:1330, 1992; R ...
The well-publicized recovery from paralysis of a professional football player has recently focused attention on the growing use of drugs to minimize the effects of spinal cord injury. Methylprednisolone sodium succinate (Solu-Medrol - Upjohn), commercially available in the USA for intravenous treatment of transplant rejection and various inflammatory and auto-immune disorders, and GM-1 ganglioside, commercially available in Italy (Sygen - Fidia) but not in the USA, are now widely used in patients with spinal cord injury.
Med Lett Drugs Ther. 1993 Aug 6;35(902):72-3 |  Show IntroductionHide Introduction

Dexrazoxane for Cardiac Protection Against Doxorubicin

   
The Medical Letter on Drugs and Therapeutics • Nov 24, 1995  (Issue 962)
(JL Speyer and R Freedberg in MD Abeloff et al, eds, Clinical Oncology, New York:Churchill Livingstone ...
Dexrazoxane (Zinecard - Pharmacia) was recently approved by the US Food and Drug Administration (FDA) for protection against cardiac toxicity from (Adriamycin, and others) in women with metastatic breast cancer.
Med Lett Drugs Ther. 1995 Nov 24;37(962):110-1 |  Show IntroductionHide Introduction

Interferon Beta-1a for Relapsing Multiple Sclerosis

   
The Medical Letter on Drugs and Therapeutics • Jul 19, 1996  (Issue 979)
effects (R Cirelli et al, Clin Immunother, 5 suppl 1:22, 1996). CLINICAL TRIALS — A multicenter ...
Interferon β-1a (Avonex - Biogen), a recombinant form of human interferon β, has been approved by the US Food and Drug Administration (FDA) for treatment of relapsing forms of multiple sclerosis (MS). Interferon β-1a (Betaseron - Berlex), a recombinant analog of interferon β that differs from interferon β-1a in having a serine substituted for a cysteine and in not being glycosylated, was previously approved for this indication (Medical Letter, 35:61, 1993; BW van Oosten et al, Drugs, 49:200, 1995).
Med Lett Drugs Ther. 1996 Jul 19;38(979):63-4 |  Show IntroductionHide Introduction

The Atkins Diet

   
The Medical Letter on Drugs and Therapeutics • Jun 12, 2000  (Issue 1080)
. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Richard Kim, M.D., Vanderbilt ...
Nearly 30 years after the first publication of Dr. Atkins' Diet Revolution promoting a high-protein, extremely low-carbohydrate diet, patients once again are asking their physicians about the Atkins diet.
Med Lett Drugs Ther. 2000 Jun 12;42(1080):52 |  Show IntroductionHide Introduction

Docosanol Cream (Abreva) for Recurrent Herpes Labialis

   
The Medical Letter on Drugs and Therapeutics • Nov 13, 2000  (Issue 1092)
of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew Maurer, M.D ...
Doconsanol 10% cream, a long-chain saturated alcohol, has been approved by the FDA for over-the-counter treatment of herpes labialis.
Med Lett Drugs Ther. 2000 Nov 13;42(1092):108 |  Show IntroductionHide Introduction

Once-a-week Alendronate (Fosamax)

   
The Medical Letter on Drugs and Therapeutics • Mar 19, 2001  (Issue 1100)
., Vanderbilt School of Medicine; F. Estelle R. Simons, M.D., University of Manitoba EDITORIAL FELLOWS: Mathew ...
Once-a-week formulations of alendronate (Fosamax) in 35- and 70-mg tablets have now been approved by the FDA and are being heavily promoted for prevention and treatment of postmenopausal osteoporosis. A new formulation of risedronate (Actonel) for once-a-week use is under development and may be available next year.
Med Lett Drugs Ther. 2001 Mar 19;43(1100):26 |  Show IntroductionHide Introduction

In Brief: Exenatide (Byetta) for Weight Loss

   
The Medical Letter on Drugs and Therapeutics • Mar 13, 2006  (Issue 1230)
of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New York ...
Patients may be asking about reports in the lay press that exenatide (Byetta - Med Lett Drugs Ther 2005; 47:45), a synthetic peptide that stimulates release of insulin from pancreatic beta cells, has been used by diabetics and non-diabetics to lose weight. Approved by the FDA to improve glycemic control in patients with type 2 diabetes not controlled by metformin, a sulfonylurea or both, it is given by subcutaneous injection before the morning and evening meals. In clinical trials, some diabetic patients treated with the drug lost weight. No data are available on use in non-diabetics....
Med Lett Drugs Ther. 2006 Mar 13;48(1230):21 |  Show IntroductionHide Introduction

In Brief: Sodium Phosphate Colonoscopy Preps

   
The Medical Letter on Drugs and Therapeutics • May 22, 2006  (Issue 1235)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
Last year, a Medical Letter article reviewing colonoscopy preparations warned that oral sodium phosphate preparations, such as Fleet Phospho-Soda solution and Visicol tablets, could cause significant electrolyte disturbances and, rarely, renal failure (Med Lett Drugs Ther 2005; 47:53). A subsequent report documented acute phosphate nephropathy and renal failure in 21 patients who had used sodium phosphate before colonoscopy (GS Markowitz et al. J Am Soc Nephrol 2005; 16:3389). Seventeen of these patients were women and 14 were taking an angiotensin-converting enzyme (ACE) inhibitor or...
Med Lett Drugs Ther. 2006 May 22;48(1235):41 |  Show IntroductionHide Introduction

In Brief: Plan B OTC

   
The Medical Letter on Drugs and Therapeutics • Sep 11, 2006  (Issue 1243)
., University Hospital, Copenhagen Dan M. Roden, M.D., Vanderbilt University School of Medicine F. Estelle R ...
The FDA has approved over-the-counter (OTC) sales of Plan B (Duramed), an emergency contraceptive package that contains two 0.75-mg tablets of levonorgestrel, to women ≥18 years old. Younger women still require a prescription. In one trial, two levonorgestrel 0.75-mg tablets taken 12 hours apart, the first within 72 hours after unprotected intercourse, decreased the pregnancy rate to 1%, compared to an expected rate of 8% (Task Force on Postovulatory Methods of Fertility Regulation, Lancet 1998; 352:428). How high doses of a progestin taken after coitus prevent pregnancy is unclear; they may...
Med Lett Drugs Ther. 2006 Sep 11;48(1243):75 |  Show IntroductionHide Introduction

Correction: Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures

   
The Medical Letter on Drugs and Therapeutics • Dec 17, 2007  (Issue 1276)
School of Medicine F. Estelle R. Simons, M.D., University of Manitoba Neal H. Steigbigel, M.D., New ...
On page 100 of the article "Major Changes in Endocarditis Prophylaxis for Dental, GI and GU Procedures", under the section Highest-Risk Procedures, the word "rubber" should have been omitted. Placement of orthodontic rubber bands is not a highest-risk procedure that justifies prophylaxis; placement of orthodontic (metal) bands is. An orthodontic band is a metal ring that surrounds the tooth and is pressed into place causing movement in closely-spaced teeth and sometimes bleeding when the bands are placed close to the gumline.
Med Lett Drugs Ther. 2007 Dec 17;49(1276):104 |  Show IntroductionHide Introduction